(Q37360623)

19 August 2017

Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival (English)

1 reference

19 August 2017

1 reference

Jenny K Hoang

2

0 references

author name string

Katherine R Birchard

series ordinal

1

1 reference

19 August 2017

James E Herndon

series ordinal

3

1 reference

19 August 2017

Edward F Patz

series ordinal

4

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 February 2009

1 reference

19 August 2017

1 reference

19 August 2017

115

1 reference

19 August 2017

581-586

1 reference

19 August 2017

3

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

19 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24060

7 January 2021

Pulmonary nodules: Interscan variability of semiautomated volume measurements with multisection CT-- influence of inspiration level, nodule size, and segmentation performance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24060

7 January 2021

Pulmonary nodules: 3D volumetric measurement with multidetector CT--effect of intravenous contrast medium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24060

7 January 2021

Pulmonary adenocarcinomas with ground-glass attenuation on thin-section CT: quantification by three-dimensional image analyzing method.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24060

7 January 2021

Pulmonary nodule volumetric measurement variability as a function of CT slice thickness and nodule morphology.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24060

7 January 2021

Histologic Assessment of Non–Small Cell Lung Carcinoma after Neoadjuvant Therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24060

7 January 2021

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24060

7 January 2021

Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24060

7 January 2021

Grading of tumor regression in non-small cell lung cancer : morphology and prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24060

7 January 2021

Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24060

7 January 2021

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24060

7 January 2021

Imaging response assessment in oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24060

7 January 2021

Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24060

7 January 2021

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24060

7 January 2021

Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24060

7 January 2021

Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24060

7 January 2021

Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24060

7 January 2021

Identifiers

DOI

10.1002/CNCR.24060

1 reference

19 August 2017

1 reference